银屑病早期治疗对疾病复发的影响:STEPIn研究结果
STEPIn研究(NCT03020199)评估新发斑块状银屑病(病程≤1年)患者早期使用司库奇尤单抗的获益。患者在第52周停用司库奇尤单抗及窄谱中波紫外线后进入无治疗随访至第104周,分析维持PASI 90应答的患者比例。结果显示部分患者停药1年后仍维持疗效。
要点
- 第104周时,既往接受司库奇尤单抗治疗者中20.8%维持PASI 90应答。
- 进入无治疗随访期的司库奇尤单抗治疗患者中,44%(29/66)至第104周未复发。
- 早期干预可在部分新发中重度银屑病患者中于停药1年后维持疗效。
核心结论
- 早期使用司库奇尤单抗干预可在部分新发中重度银屑病患者中于停药1年后维持疗效。
研究设计与样本
- STEPIn研究(NCT03020199),评估新发斑块状银屑病(病程≤1年)患者早期使用司库奇尤单抗的获益,第52周停用司库奇尤单抗及窄谱中波紫外线后随访至第104周。
- 采用Wald检验分析第52周至第104周达到PASI 90(关键次要终点)的患者比例,缺失值采用无应答者填补法。
主要发现
- 司库奇尤单抗组93.5%(72/77)患者完成52周治疗。
- 第104周时,既往接受司库奇尤单抗治疗者中20.8%维持PASI 90应答。
- 第104周时,既往接受司库奇尤单抗治疗者中分别有11.7%、22.1%和24.7%维持PASI 100应答、IGA mod 2011 0/1和PASI <3。
- 司库奇尤单抗治疗患者中,第52周进入无治疗随访期的44%(29/66)至第104周未复发(复发定义为治疗停止后PASI最大改善丧失50%)。
关键数值与推荐
- PASI 90为关键次要终点,分析区间为第52周至第104周。
- 复发定义为治疗停止后PASI最大改善丧失50%。
临床怎么用
- 对新发中重度银屑病患者早期使用司库奇尤单抗,部分患者停药1年后仍可维持疗效。
局限性
- 研究为开放标签设计,缺乏盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benefits of early intervention with secukinumab in patients with new-onset plaque psoriasis (disease duration: ≤1 year) were investigated in STEPIn study (NCT03020199). OBJECTIVE: To evaluate the proportion of patients maintaining sustained skin clearance in the treatment-free follow-up period up to week (W) 104 following withdrawal of secukinumab and narrow band ultraviolet B at W52. METHODS: Wald test was used for analysis of proportion of patients achieving PASI 90 (key secondary endpoint) from W52 through W104. Missing values were imputed using nonresponder imputation approach. RESULTS: Overall, 93.5% (72/77) of patients completed 52 weeks in the secukinumab arm. At W104, 20.8% of patients who previously received secukinumab sustained PASI 90 responses. At W104, 11.7%, 22.1%, and 24.7% of patients previously treated with secukinumab sustained a PASI 100 response, IGA mod 2011 0/1 and PASI <3. Among secukinumab treated patients, 44% (29/66) who entered the treatment-free follow-up period at W52 did not relapse (loss of 50% of the maximum improvement in PASI following treatment cessation) until W104. LIMITATION: Absence of blinding due to open-label nature of the study. CONCLUSIONS: Early intervention with secukinumab maintains efficacy in a subset of patients with new-onset moderate to severe psoriasis, 1-year following treatment withdrawal.
引用
- Iversen L, Langley RG, Gudjonsson JE, et al. Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study. J Am Acad Dermatol. 2026. PMID: 41881197. doi:10.1016/j.jaad.2026.03.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。